An observational study in Anosmia, Chronic Obstructive Pulmonary Disease and Hyposmia, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational
Background:
Exposure to smoke increases the risk of many diseases. People can be exposed to dangerous levels of smoke during wildfires. Also, smoke from fires that burn manmade materials may contain toxic chemicals. Researchers want to know more about how breathing smoke affects a person s airways (nose, sinuses, lungs) and immune system.
Objective:
To learn how exposure to smoke over time affects the health of people who work as firefighters.
Eligibility:
Healthy, nonsmoking people aged 18 to 65 years who work as firefighters. Some people older than 65 may also be included.
Design:
Participants will have study visits about every 6 months for up to 10 years. They will also have visits after a smoke exposure event. Some visits may be by telehealth. Each visit will include some or all of the following:
Imaging scans of the sinuses or chest.
Sample collection. These will include blood, nasal fluids, a skin swab, urine, and fluid coughed up from the lungs.
Lung function test. Participants will blow air into a machine that measures the volume moving in and out of their lungs.
Particles in exhaled air (PExA). Participants will breathe into a device that collects particles.
Heart function test.
Smell test. Participants will identify odors on scratch-and-sniff cards.
Wearable air monitors. Participants may be asked to wear a device that measures particles and chemicals in the air around them for 1 to 20 days.
International Public Safety Data Institute (IPSDI) reports. Participants will provide copies of these fire suppression event reports, if they are available.
Participants who have exams of the airways as part of their routine health care may have extra tissue samples collected for research.
Study Description:
This observational natural history study (FLARES) will define the acute and longterm airway, respiratory and immune consequences of anthropogenic smoke exposures that arise from urban and wildland urban interface (WUI) fires. Given their disproportionate exposure, firefighters will be used as a model. The protocol integrates (1) standardized clinical phenotyping, (2) detailed exposure assessment, and (3) multi-omic profiling to enable evidence-based management of smoke- and pollutant-related respiratory impairment.
FLARES will enroll firefighter recruits and active-duty firefighters. Firefighters will be followed longitudinally with twice annual visits to the NIH Clinical Center (NIH CC) and will undergo event-driven evaluations including paired pre- and postexposure assessments around planned fire exposures (eg, live fire simulations) and assessments following unplanned exposures. Systematic evaluation of the upper and lower airways will be coupled with an exposure-informed biorepository of biospecimens - blood, nasal lining fluid, particulates exhaled from deep airways and urine- for multi-omic and exposome analyses to elucidate molecular pathways of smoke- and chemical -related injury. Assessments will include sinus and chest imaging (baseline and 3-year CT with interval magnetic resonance imaging [MRI]), pulmonary function testing (PFT), and detailed exposure questionnaires. Pre/post exposure comparisons and longitudinal trajectories of firefighters will be used to identify early biomarkers, multi-omic trajectories, and clinical indices of perturbed respiratory immunity and sinopulmonary disease in relation to exposure characteristics (eg, frequency, duration, intensity, and fire type), including the growing burden of anthropogenic smoke exposures in the context of climate change.
Objectives:
Primary Objective: Assess changes in multi-omic signatures within airway epithelium/fluids, peripheral blood, and/or urine following anthropogenic smoke exposure.
Secondary Objective: Determine development or progression of upper and/or lower airway disease following anthropogenic smoke exposure at a 3-year interval.
Tertiary Objective: Assess multi-site exposome shifts following anthropogenic smoke exposure.
Exploratory Objectives:
Endpoints:
Primary Endpoints:
Fold differences in methylation, transcription, proteomic and/or metabolic pathways:
Primary endpoints may be assessed in context of acute exposures: 0-14 days after defined smoke exposure episode, subacute (15-90 days) post exposure, and chronic (repeated and/or > 90 days post exposure).
Secondary Endpoints: 3-year incidence of participant-reported symptoms corroborated by objective physiologic or inflammatory changes.
1 or more domains identified as meeting at least 1 subjective measure AND at least
1 corresponding objective measure (eg, Chronic Airway Assessment
Test [CAAT] >= 8 AND fractional exhaled nitric oxide [FeNO] > 50 ppb).
Tertiary Endpoint: Direct or estimated smoke chemical levels on wearable, under uniform monitors relative to neutral-location controls (eg, fire station or home) and post-exposure urine versus pre-exposure urine.
Exploratory Endpoints:
120 studies on the registry are indexed under Anosmia; 39 are open to participants now.
This study's planned enrollment of 350 is above the median of 218 across 33 observational studies indexed under Anosmia.
Browse Anosmia studies →National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,445 studies on the registry; 182 are open to participants now.
Of its 402 completed or terminated interventional studies of FDA-regulated products, 300 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Healthy firefighter cadets, recruits and active-duty firefighters aged 18 to 65 without history of recreational smoke exposure who are employed within the Maryland, Virginia, and the District of Columbia area.
To be eligible to participate in this study, an individual must meet all of the following criteria:
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
Presence of condition(s) that, in the judgment of the investigator or the referring physician, may put the participant at undue risk or make them unsuitable for participation
in the study.
Participants will be selected in an equitable manner from the available pool of potentially eligible individuals, without regard to factors such as sex, race, ethnicity, socioeconomic status, etc, except for age, as described below. We note that, given their non-volunteer (ie salaried) status, active-duty firefighters and recruits are screened by NFPA Form 1582 for medical conditions precluding active firefighting duties, which is inclusive of above conditions with the exception of known inborn error of immunity.
Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the principal investigator. Study staff should be notified of co-enrollment on any other protocol.
Exclusion of Special Populations:
-Adults Over the Age of 65
Federal firefighters have a maximum retirement age of 57 years; although there are local departments with individuals over this age. Firefighters over the age of 65 at enrollment who meet all other eligibility criteria will require special permission from investigators to participate in this study. Exceptions will be made on a case-by-case basis to ensure that age-matched cases do not skew disproportionately to an older population.
-Adults Who Lack, or Lose, Decision-Making Capacity to Consent to Research Participation
Given the known dangers associated with firefighting, it would be unethical to include individuals who lack decision-making capacity to consent.
-Exclusion During Pregnancy
Women who are/become pregnant will be excluded from the study while pregnant and/or lactating given condition specific physiology that may confound the objectives of the study. In the event of pregnancy in a study participant, the participant will temporarily pause all study related activities. Participants may resume study activities 4 weeks after the conclusion of the pregnancy or cessation of lactation.
-Children
Children will be excluded from this study given the age minimums to attend firefighting academies.
Healthy firefighter cadets, recruits and active-duty firefighters aged 18 to 65 without history of recreational smoke exposure who are employed within the Maryland, Virginia, and the District of Columbia area.
Fold differences in methylation, transcription, proteomic and/or metabolic pathways:1. After defined smoke exposure episode 2. Subacute post exposure 3. Chronic (repeated and/or > 90 days post exposure
Assess changes in multi-omic signatures within airway epithelium/fluids, peripheral blood, and/or urine following anthropogenic smoke exposure
Time frame: 1. 0-14 days 2. 15-90 days 3. > 90 days
Incidence of participant-reported symptoms corroborated by objective physiologic or inflammatory changes. 1 or more domains identified as meeting at least 1 subjective measure and at least 1 corresponding objective measure, eg, CAAT > 8 AND F...
Determine development or progression of upper and/or lower airway disease following anthropogenic smoke exposure at a 3-year interval
Time frame: 3 year interval
Plan to share: Yes — Raw de-identified data will be shared per NIH Data Sharing Policy and publication requirements.@@@@@@
Supporting information: Study protocol, Analytic code
Time frame: Exact time frame is unknown. Will be completed per NIH Data Sharing Policy and publication requirements.@@@@@@
Access criteria: Per PI discretion and repository requirements.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Allergy and Infectious Diseases (NIAID) →